HETEs enhance IL-1-mediated COX-2 expression via augmentation of message stability in human colonic myofibroblasts

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 293, Issue 4, 2007, Pages

  Di Mari, J F ^a,b   Saada, J I ^a   Mifflin, R C ^a   Valentich, J D ^c   Powell, D W ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c NONE

Author keywords

Colorectal cancer; Cyclooxygenases; Lipoxygenases; Prostaglandins

Indexed keywords

5,6 DICHLORO BETA DEXTRO RIBOFURANOSYLBENZIMIDAZOLE; ANTIGEN; BENZIMIDAZOLE; CYCLOOXYGENASE 2; CYTOKINE; HUMAN ANTIGEN R RNA BINDING PROTEIN; HYDROXYICOSATETRAENOIC ACID; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE ACTIVATED PROTEIN KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTAGLANDIN E2; PROTEIN KINASE; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CELL NUCLEUS; COLON; COLON ADENOMA; CONTROLLED STUDY; ENTERITIS; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; MYOFIBROBLAST; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANTIGENS, SURFACE; ARACHIDONATE 5-LIPOXYGENASE; CELLS, CULTURED; COLON; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME ACTIVATION; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; INTERLEUKIN-1ALPHA; INTESTINAL MUCOSA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 35349000662     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00117.2007     Document Type: Article

References (86)

1. Adegboyega PA, Mifflin RC, DiMari JF, Saada JI, Powell DW. Immunohistochemical study of myofibroblasts in normal colonic mucosa, hyperplastic polyps and adenomatous colorectal polyps. Arch Pathol Lab Med 126: 829-836, 2002.
2. Adegboyega PA, Mifflin RC, Saada JI, DiMari JF, Powell DW. COX-2 is localized to stromal cells in human colorectal adenomas (Abstract). Gastroenterology 120: A162, 2001.
3. Adegboyega PA, Ololade O, Saada J, Mifflin R, Di Mari JF, Powell DW. Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas. Clin Cancer Res 10: 5870-5879, 2004.
4. Ashwood P, Harvey R, Verjee T, Wolstencroft R, Thompson RP, Powell JJ. Functional interactions between mucosal IL-1, IL-ra and TGF-beta 1 in ulcerative colitis. Inflamm Res 53: 53-59, 2004.
5. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60: 4629-4637, 2000.
6. Backlund MG, Mann JR, Dubois RN. Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology 69, Suppl 1: 28-32, 2005.
7. Bemis-Standoli K, Cox L, Kasa V, Lynch M, Ford H, Coffey RJ, Dixon DA. Role of the mRNA stability factor HuR in inflammatory bowel disease and colon carcinogenesis (Abstract). Gastroenterology 130: A-45, 2006.
8. Blazovics A, Hagymasi K, Pronai L. [Cytokines, prostaglandins, nutritive and non-nutritive factors in inflammatory bowel diseases]. Orv Hetil 145: 2523-2529, 2004.
9. Bortuzzo C, Hanif R, Kashfi K, Staiano-Coico L, Shiff SJ, Rigas B. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim Biophys Acta 1300: 240-246, 1996.
10. Brennan CM, Steitz JA. HuR and mRNA stability. Cell Mol Life Sci 58: 266-277, 2001.
11. Bulger EM, Maier RV. Lipid mediators in the pathophysiology of critical illness. Crit Care Med 28: N27-N36, 2000.
12. Bus PJ, Nagtegaal ID, Verspaget HW, Lamers CB, Geldof H, Van Krieken JH, Griffioen G. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther 13: 1397-1402, 1999.
13. Celotti F, Durand T. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Prostaglandins Other Lipid Mediat 71: 147-162, 2003.
14. Celotti F, Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol Res 43: 429-436, 2001.
15. Cha YI, Dubois RN. NSAIDS and cancer prevention: targets downstream of COX-2. Annu Rev Med 58: 239-252, 2007.
16. Cok SJ, Acton SJ, Morrison AR. The proximal region of the 3′-untranslated region of cyclooxygenase-2 is recognized by a multimeric protein complex containing HuR, TIA-1, TIAR, and the heterogeneous nuclear ribonucleoprotein U. J Biol Chem 278: 36157-36162, 2003.
17. Craven PA, DeRubertis FR. Profiles of eicosanoid production by superficial and proliferative colonic epithelial cells and sub-epithelial colonic tissue. Prostaglandins 32: 387-399, 1986.
18. Dean JL, Sully G, Clark AR, Saklatvala J. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal 16: 1113-1121, 2004.
19. Di Marco S, Hel Z, Lachance C, Furneaux H, Radzioch D. Polymorphism in the 3′-untranslated region of TNFalpha mRNA impairs binding of the post-transcriptional regulatory protein HuR to TNFalpha mRNA. Nucleic Acids Res 29: 863-871, 2001.
20. Di Mari JF, Mifflin RC, Adegboyega PA, Saada JI, Powell DW. IL-1alpha-induced COX-2 expression in human intestinal myofibroblasts is dependent on a PKCzeta-ROS pathway. Gastroenterology 124: 1855-1865, 2003.
21. DiMari JF, Mifflin RC, Saada JI, Adegboyega PA, Powell DW. IL-1 induces Cox-2 protein synthesis in intestinal stromal cells via MAPK and PKC-dependent pathways (Abstract). Gastroenterology 120: A5, 2001.
22. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 87:2095-2147, 1996.
23. Ding XZ, Hennig R, Adrian TE. Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer. Mol Cancer 2: 10, 2003.
24. DuBois RN, Eberhart CF, Williams CS. Introduction to eicosanoids and the gastroenteric tract. Gastroenterol Clin North Am 25: 267-277, 1996.
25. Edwards RA, Smock AZ. Defective arachidonate release and PGE2 production in Gi alpha2-deficient intestinal and colonic subepithelial myofibroblasts. Inflamm Bowel Dis 12: 153-165, 2006.
26. Giardiello FM, Casero RA Jr, Hamilton SR, Hylind LM, Trimbath JD, Geiman DE, Judge KR, Hubbard W, Offerhaus GJ, Yang VW. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology 126: 425-431, 2004.
27. Graham DY, Smith JL, Holmes GI, Davies RO. Nonsteroidal antiinflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa. Clin Pharmacol Ther 38: 65-70, 1985.
28. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11-21, 2001.
29. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J. Prostaglandin E(2) protects intestinal tumors from nonsteroidal antiinflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 62: 403-408, 2002.
30. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. Gastroenterology 112: 718-724, 1997.
31. Hennig R, Ding XZ, Tong WG, Witt RC, Jovanovic BD, Adrian TE. Effect of LY293111 in combination with gemcitabine in colonic cancer. Cancer Lett 210: 41-46, 2004.
32. - secretion in T84 cells. Am J Physiol Cell Physiol 271: C1262-C1268, 1996.
33. Hommes DW, Meenan J, de Haas M, ten Kate FJ, von dem Borne AE, Tytgat GN, van Deventer SJ. Soluble Fc gamma receptor III (CD 16) and eicosanoid concentrations in gut lavage fluid from patients with inflammatory bowel disease: reflection of mucosal inflammation. Gut 38: 564-567, 1996.
34. Hong SH, Avis I, Vos MD, Martinez A, Treston AM, Mulshine JL. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 59: 2223-2228, 1999.
35. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 34: 742-747, 1993.
36. Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 103: 1587-1595, 1992.
37. Jaffe BM, Parker CW, Philpott GW. Immunochemical measurement of prostaglandin or prostaglandin-like activity from normal and neoplastic cultured tissue. Surg Forum 22: 90-92, 1971.
38. Jampilek J, Dolezal M, Opletalova V, Hartl J. 5-Lipoxygenase, leukotrienes biosynthesis and potential antileukotrienic agents. Curr Med Chem 13: 117-129, 2006.
39. Kobayashi K, Fukuda T, Higuchi K, Nakamura H, Arakawa T. Role of leukotrienes in indomethacin-induced mucosal damage in rats. J Clin Gastroenterol 17, Suppl 1: S11-S14, 1993.
40. Korzenik JR, Podolsky DK. Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease. Clin Gastroenterol Hepatol 4: 157-159, 2006.
41. Krimsky M, Yedgar S, Aptekar L, Schwob O, Goshen G, Gruzman A, Sasson S, Ligumsky M. Amelioration of TNBS-induced colon inflammation in rats by phospholipase A2 inhibitor. Am J Physiol Gastrointest Liver Physiol 285: G586-G592, 2003.
42. Lasa M, Mahtani KR, Finch A, Brewer G, Saklatvala J, Clark AR. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol Cell Biol 20: 4265-4274, 2000.
43. Lawson LD, Powell DW. Bradykinin-stimulated eicosanoid synthesis and secretion by rabbit ileal components. Am J Physiol Gastrointest Liver Physiol 252: G783-G790, 1987.
44. Lopez de Silanes I, Fan J, Galban CJ, Spencer RG, Becker KG, Gorospe M. Global analysis of HuR-regulated gene expression in colon cancer systems of reducing complexity. Gene Expr 12: 49-59, 2004.
45. Lopez de Silanes I, Lal A, Gorospe M. HuR: post-transcriptional paths to malignancy. RNA Biol 2: 11-13, 2005.
46. MacDermott RP. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am J Gastroenterol 95: 3343-3345, 2000.
47. MacGregor DJ, Kim YS, Sleisenger MH, Johnson LK. Chemoprevention of colon cancer carcinogenesis by balsalazide: inhibition of azoxymethane-induced aberrant crypt formation in the rat colon and intestinal tumor formation in the B6-Min/+ mouse. Int J Oncol 17: 173-179, 2000.
48. Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 97: 910-914, 2002.
49. Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA, Papadakis KA. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis 10: 352-356, 2004.
50. Mifflin RC, Saada JI, Di Mari JF, Adegboyega P, Powell DW. Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction. Am J Physiol Cell Physiol 282: C824-C834, 2002.
51. Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW. Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol 65: 470-478, 2004.
52. Mrena J, Wiksten JP, Thiel A, Kokkola A, Pohjola L, Lundin J, Nordling S, Ristimaki A, Haglund C. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res 11: 7362-7368, 2005.
53. Nielsen CK, Campbell JI, Ohd JF, Morgelin M, Riesbeck K, Landberg G, Sjolander A. A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res 65: 732-742, 2005.
54. Ohd JF, Nielsen CK, Campbell J, Landberg G, Lofberg H, Sjolander A. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 124: 57-70, 2003.
55. Ohd JF, Wikstrom K, Sjolander A. Leukotrienes induce cell-survival signaling in intestinal epithelial cells. Gastroenterology 119: 1007-1018, 2000.
56. Parhamifar L, Jeppsson B, Sjolander A. Activation of cPLA2 is required for leukotriene D4-induced proliferation in colon cancer cells. Carcinogenesis 26: 1988-1998, 2005.
57. Peterson JW, Dickey WD, Saini SS, Gourley W, Klimpel GR, Chopra AK. Phospholipase A2 activating protein and idiopathic inflammatory bowel disease. Gut 39: 698-704, 1996.
58. Podolsky DK, Fiocchi C. Cytokines, chemokines, growth factors, eicosanoids, and other bioactive molecules in inflammatory bowel disease. In: Inflammatory Bowel Disease, edited by Kirsner JB. Philadelphia, PA: Saunders, 2000, p. 191-207.
59. Pommery N, Taverne T, Telliez A, Goossens L, Charlier C, Pommery J, Goossens JF, Houssin R, Durant F, Henichart JP. New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy. J Med Chem 47: 6195-6206, 2004.
60. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122: 518-523, 1993.
61. Rubin DT, Lashner BA. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol 100: 1354-1356, 2005.
62. Rubin DT, LoSavio A, Yadron N, Huo D, Hanauer SB. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 4: 1346-1350, 2006.
63. Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, Kent JD, Bloom BJ. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 4: 203-211, 2006.
64. Serrano-Mollar A, Closa D. Arachidonic acid signaling in pathogenesis of allergy: therapeutic implications. Curr Drug Targets Inflamm Allergy 4: 151-155, 2005.
65. Shannon VR, Stenson WF, Holtzman MJ. Induction of epithelial arachidonate 12-lipoxygenase at active sites of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 264: G104-G111, 1993.
66. Shattuck-Brandt RL, Varilek GW, Radhika A, Yang F, Washington MK, DuBois RN. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology 118: 337-345, 2000.
67. Singh VP, Patil CS, Jain NK, Singh A, Kulkarni SK. Effect of nimesulide on acetic acid- and leukotriene-induced inflammatory bowel disease in rats. Prostaglandins Other Lipid Mediat 71: 163-175, 2003.
68. Song H, Ki SH, Kim SG, Moon A. Activating transcription factor 2 mediates matrix metalloproteinase-2 transcriptional activation induced by p38 in breast epithelial cells. Cancer Res 66: 10487-10496, 2006.
69. Stenson WF. Role of eicosanoids as mediators of inflammation in inflammatory bowel disease. Scand J Gastroenterol Suppl 17250: 13-18, 1990.
70. Stenson WF, Parker CW. Monohydroxyeicosatetraenoic acids (HETEs) induce degranulation of human neutrophils. J Immunol 124: 2100-2104, 1980.
71. Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ. Regulation of cyclooxygenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 278: 37637-37647, 2003.
72. Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, Bjornsson E, Bjarnason I. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 4: 196-202, 2006.
73. ten Hove T, van den Blink B, Pronk I, Drillenburg P, Peppelenbosch MP, van Deventer SJ. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 50: 507-512, 2002.
74. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991.
75. Tries S, Neupert W, Laufer S. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 51: 135-143, 2002.
76. Valentich JD, Popov V, Saada JI, Powell DW. Phenotypic characterization of an intestinal subepithelial myofibroblast cell line. Am J Physiol Cell Physiol 272: C1513-C1524, 1997.
77. van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54: 1573-1578, 2005.
78. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100: 1345-1353, 2005.
79. Wallace JL, MacNaughton WK, Morris GP, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96: 29-36, 1989.
80. Wang D, Dubois RN. Prostaglandins and cancer. Gut 55: 115-122, 2006.
81. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, DuBois RN. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 203: 941-951, 2006.
82. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, Das SK, Dey SK, DuBois RN. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6: 285-295, 2004.
83. Wendum D, Comperat E, Boelle PY, Parc R, Masliah J, Trugnan G, Flejou JF. Cytoplasmic phospholipase A2 alpha overexpression in stromal cells is correlated with angiogenesis in human colorectal cancer. Mod Pathol 18: 212-220, 2005.
84. Yang VW. Eicosanoids and inflammatory bowel disease. Gastroenterol Clin North Am 25: 317-332, 1996.
85. Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, Cho CH. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 26: 827-834, 2005.
86. Youngman KR, Simon PL, West GA, Cominelli F, Rachmilewitz D, Klein JS, Fiocchi C. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 104: 749-758, 1993.